From the Editor ’s desk....

The changing frequency in the listing of patients with end-stage HCV-induced liver disease for transplant, and the improvement of the typically impaired post-transplant survival seen in these patients, can be taken as early and strong indicators of direct acting antiviral (DAA) therapy ’s positive impact on HCV-associated disease burden. The study by Crespo et al. compared the composition of the liver transplant waiting list and the early post-transplant survival in the years before and after the availability of DAAs.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Desk Source Type: research